Valuation: Colinz Laboratories Limited

Market Cap 185M 1.93M 1.71M 1.6M 1.46M 2.75M 2.77M 19.33M 7.49M 94.65M 7.23M 7.07M 304M P/E 2025
36.8x
P/E 2026 21.8x
Enterprise Value 104M 1.08M 959K 895K 816K 1.54M 1.55M 10.83M 4.2M 53.04M 4.05M 3.96M 170M EV / Sales 2025
2.04x
EV / Sales 2026 0.5x
Free-Float
31.44%
Yield 2025 *
-
Yield 2026 -
08-19 Annjana Dugar, Likhitta Dugar and Antariksh Dugar completed the acquisition of an additional 0.000238% stake in Colinz Laboratories Limited for INR 324. CI
07-30 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million. CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
05-25 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
04-29 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
01-24 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-16 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
11-27 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
11-08 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
11-03 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
25-07-31 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-21 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
1 day-4.16%
1 week-3.54%
Current month-4.16%
1 month+5.59%
3 months-9.96%
6 months+68.15%
Current year+37.05%
1 week 71.1
Extreme 71.1
78.7
1 month 68.1
Extreme 68.1
78.7
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 35.2
Extreme 35.2
88.7
5 years 18.05
Extreme 18.05
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 74 -
Director of Finance/CFO - 2019-05-19
Compliance Officer - 2025-11-30
Director TitleAgeSince
Director/Board Member 74 1990-11-25
Director/Board Member 34 2024-08-07
Director/Board Member 76 2024-08-07
Change 5-day change 1-year change 3-year change Capi.($)
-4.16%-3.54%+69.79%+79.71% 1.92M
-0.61%-3.43%+39.40%+112.31% 1,025B
-1.02%-5.60%+37.67%+65.02% 623B
+1.11%-0.58%+11.10%+77.28% 459B
+0.34%-3.01%+61.21%+40.71% 355B
-0.95%-4.05%+21.60%+39.37% 336B
-1.46%-2.89%+11.84%+24.60% 270B
-1.35%-5.43%-4.69%+8.40% 247B
-1.04%-2.79%+35.52%+51.34% 220B
-1.87%-4.10%+30.92%+95.33% 183B
Average -0.63%-3.03%+31.43%+59.41% 371.82B
Weighted average by Cap. +0.42%-3.17%+30.51%+68.92%

Financials

2025 2026
Net sales 65.28M 679K 603K 563K 513K 968K 977K 6.81M 2.64M 33.37M 2.55M 2.49M 107M 61.36M 638K 567K 529K 482K 910K 918K 6.41M 2.48M 31.37M 2.4M 2.34M 101M
Net income 4.97M 51.66K 45.9K 42.84K 39.05K 73.64K 74.33K 518K 201K 2.54M 194K 190K 8.15M 5.14M 53.52K 47.55K 44.38K 40.45K 76.29K 77K 537K 208K 2.63M 201K 197K 8.44M
Net Debt -49.09M -511K -454K -423K -386K -728K -735K -5.12M -1.99M -25.1M -1.92M -1.88M -80.55M -81.39M -847K -752K -702K -640K -1.21M -1.22M -8.5M -3.29M -41.61M -3.18M -3.11M -134M
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
62
Date Price Change Volume
26-10-01 ₹73.50 -4.16% 2,711
26-09-30 ₹76.69 +2.31% 3,879
26-09-29 ₹74.96 +0.35% 1,319
26-09-28 ₹74.70 -1.97% 741
26-09-25 ₹76.20 +1.60% 263
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock